Advertisement
UK markets open in 6 hours 12 minutes

  • NIKKEI 225

    37,611.72
    -16.76 (-0.04%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • CRUDE OIL

    83.89
    +0.32 (+0.38%)
     

  • GOLD FUTURES

    2,341.40
    -1.10 (-0.05%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • Bitcoin GBP

    51,327.30
    -398.27 (-0.77%)
     

  • CMC Crypto 200

    1,389.48
    +6.91 (+0.50%)
     

  • NASDAQ Composite

    15,611.76
    -100.99 (-0.64%)
     

  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

U.S FDA strengthens warnings on Glaxo, Roche/Biogen cancer drugs

Reuters - UK Focus

Sept 25 (Reuters) - U.S. regulators strengthened the warning labels on two cancer drugs - GlaxoSmithKline Plc (Other OTC: GLAXF - news) 's Arzerra, and Rituxan, made by Biogen Idec Inc (NasdaqGS: BIIB - news) and Roche Holding AG - to reflect the risk that they can reactivate the hepatitis B virus in patients previously infected with it.

The U.S. Food and Drug Administration said the risk is already described in the warnings and precautions section of the label for both drugs. Now the information will be placed in a black box, indicating the most serious type of risk.